BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS 30.06.2025, 07:00 Uhr von EQS News Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
BioVersys 28,30 CHF +22,51 % SIX Swiss (CHF)

BioVersys AG / Key word(s): AGMEGM
BIOVERSYS ANNOUNCES RESULTS FROM its ANNUAL GENERAL MEETING OF SHAREHOLDERS

30-Jun-2025 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 LR

 

Basel, Switzerland. June 30, 2025, 7am CEST

 

 

 

BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant ("MDR") bacteria, today announced the results of the Company’s Annual General Meeting (AGM) of Shareholders held on June 27, 2025.

 

A total of 55.4% of the Company’s share capital was represented at the meeting.

 

All items on the agenda received the required majority of votes in favor, including:

 

  • The Company’s 2024 Annual Report, including the Annual Financial Statements and Consolidated Financial Statements for the year ending December 31, 2024
  • The re-election of Seng Chin Mah as Chairman of the Board of Directors and the re-election of David Hunstad, Marc Gitzinger, Marina von Schönau and William Jenkins as Members of the Board of Directors in addition to the election of Ulrik Schulze as a Member of the Board of Directors
  • An amendment to the Company’s capital range and an increase to the conditional share capital for financing, acquisitions and other purposes to provide the Board of Directors with greater flexibility to respond to business opportunities and enhance BioVersys’ ability to pursue strategic initiatives

 

 

Dr. Seng Chin Mah, Chairman of the Board of the Directors commented: “I would like to thank our shareholders for their continued strong support of our strategy as we embark on the final clinical development phase for BV100 with the initiation of Phase 3 later in the year. We will also continue to progress our second clinical asset, alpibectir, as well as our preclinical projects. We remain committed to bringing our novel therapies to patients in dire need and to returning stakeholder value. The Board of Directors and Management would also like to thank Dr. Henni Ropponen for her invaluable contributions during her board tenure and we welcome Dr. Ulrik Schulze to the Board of Directors.

 

 

The minutes and the relevant documents relating to the shareholders’ meeting, including the Annual Report, will be available on the Company’s website under the following links:

Annual Report: https://ir.bioversys.com/investor-relations/financials/financial-reports

AGM: https://ir.bioversys.com/investor-relations/governance-csr/annual-general-meeting

 


About BioVersys
BioVersys AG is a multi-asset, clinical stage biopharmaceutical company focused on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (“MDR”) bacteria. Derived from the Company’s two internal technology platforms (TRIC and Ansamycin Chemistry), candidates are designed and developed to overcome resistance mechanisms, block virulence production and directly affect the pathogenesis of harmful bacteria towards the identification of new treatment options in the antimicrobial and microbiome fields. This enables BioVersys to address the high unmet medical need for new treatments against life-threatening resistant bacterial infections and bacteria-exacerbated chronic inflammatory microbiome disorders. The Company’s most advanced research and development programs address nosocomial infections of Acinetobacter baumannii (BV100, Phase 3 ready), and tuberculosis (alpibectir, Phase 2a, in collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, France). BioVersys is located in the biotech hub of Basel, Switzerland. 

BioVersys contact 
Hernan Levett,
CFO, Tel. +41 61 633 22 50; Mail: hernan.levett@bioversys.com
Website: www.bioversys.com



End of Inside Information

2162098  30-Jun-2025 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Weitere News

Gestern 22:15 Uhr • Artikel • dpa-AFX

Gestern 22:14 Uhr • Artikel • dpa-AFX

Gestern 22:01 Uhr • Artikel • dpa-AFX

Gestern 22:00 Uhr • Artikel • dpa-AFX

Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer